

Proteomics

Part I: Technologies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

ABOUT THIS REPORT

The proteomics report started as an expansion of the chapter on proteomics in Prof. Jain's report on "The Impact of Genomics on Drug Discovery and Development" published by Decision Resources Inc in 1999 and has been constantly updated since its publication as a separate report in 2000 by Jain PharmaBiotech as the first commercial report on this topic. It has been rewritten several times since then.

November 2021 (continuously published since 2000)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Basics of Proteomics.....	19
Introduction	19
History.....	19
Nucleic acids, genes and proteins	20
Genome.....	20
DNA	21
RNA	21
MicroRNAs	22
Decoding of mRNA by the ribosome	23
Genes.....	23
Alternative splicing.....	23
Transcription	24
Gene regulation	25
Gene expression	25
Chromatin.....	26
Golgi complex.....	26
Proteins	27
Functions of proteins	27
Proteasome.....	28
Spliceosome.....	28
Inter-relationship of protein, mRNA and DNA.....	29
Microproteins	30
Proteomics.....	30
Endoplasmic reticulum.....	31
Mitochondrial proteome	32
S-nitrosoproteins in mitochondria	32
Proteomics and genomics	32
Classification of proteomics	35
Levels of functional genomics and various "omics"	35
Glycoproteomics	35
Transcriptomics	36
Metabolomics	36
Cytomics.....	36
Phenomics	36
Impact of the genetic factors on the human proteome	37
Proteomics and systems biology.....	37
Proteomics and synthetic biology	38
Functional synthetic proteins	38
Synthetic proteomics for study of apoptosis	39
2. Proteomic Technologies.....	41
Key technologies driving proteomics	41
Sample preparation	42
New trends in sample preparation.....	42
Pressure Cycling Technology	43
Protein separation technologies	43
High resolution 2DGE	44
Variations of 2D gel technology	44
Limitations of 2DGE and measures to overcome these	44
1-D sodium dodecyl sulfate (SDS) PAGE	45
Capillary electrophoresis systems.....	45
Head column stacking capillary zone electrophoresis	45
Removal of albumin and IgG	46
SeraFILE™ separations platform	46
Companies with protein separation technologies	46
Protein purification.....	48
Technologies for protein purification	48
Applications of protein purification	48
Protein detection	48
Protein identification and characterization	49
Mass spectrometry	49
Electrospray ionization.....	49
Desorption electrospray ionization MS	51
Ion-mobility spectrometry-MS	51
Mirosaic 3500 MiD.....	52

Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry	52
Cryogenic MALDI- Fourier Transform Mass Spectrometry	54
Stable-isotope-dilution tandem mass spectrometry	54
HUPO Gold MS Protein Standard	54
Companies involved in mass spectrometry	55
High performance liquid chromatography	55
Multidimensional protein identification technology (MudPIT)	56
Multiple reaction monitoring assays.....	56
Peptide mass fingerprinting	57
Current status and future prospects of clinical mass spectrometry	57
Combination of protein separation technologies with mass spectrometry.....	58
Combining capillary electrophoresis with mass spectrometry	58
2D PAGE and mass spectrometry	58
Quantification of low abundance proteins	59
SDS-PAGE.....	59
Proteomics quantification in complex samples	59
Antibodies and proteomics	60
Detection of fusion proteins.....	60
Labeling and detection of proteins.....	60
Bioorthogonal non-canonical amino-acid-tagging techniques	61
Stable-isotope labeling of amino acids in cell culture	61
Fluorescent labeling of proteins in living cells.....	61
Combination of microspheres with fluorescence	62
Self-labeling protein tags	62
Analysis of peptides	62
C-terminal peptide analysis	63
Differential Peptide Display	63
Peptide analyses using NanoLC-MS	64
Protein sequencing	65
Real-time PCR for protein quantification.....	65
Quantitative proteomics	66
MS-based quantitative proteomics	66
MS and cryo-electron tomography.....	66
Selected reaction monitoring MS.....	66
Functional proteomics: technologies for studying protein function.....	67
Functional genomics by mass spectrometry.....	67
LC-MS-based method for annotating the protein-coding genome	67
RNA-Protein fusions	68
Designed repeat proteins.....	68
Application of nanobiotechnology to proteomics	68
Nanoproteomics.....	69
Nanoflow liquid chromatography	69
Nanopores for phosphoprotein analysis.....	69
Nanotube electronic biosensor for proteomics	69
Protein nanocrystallography	70
Single-molecule mass spectrometry using a nanopore	70
Nanoelectrospray ionization.....	70
Nanoproteomics for discovery of protein biomarkers in the blood	71
QD-protein nanoassembly	71
Nanoparticle barcodes	71
Biobarcode assay for proteins.....	72
Nanopore-based protein sequencing.....	73
Nanoscale protein analysis.....	73
Nanoscale mechanism for protein engineering	74
Nanotube electronic biosensor	74
Nanotube-vesicle networks for study of membrane proteins	75
Qdot-nanocrystals.....	75
Resonance Light Scattering technology	75
Study of single membrane proteins at subnanometer resolution	76
Protein expression profiling.....	76
Cell-based protein assays	77
Living cell-based assays for protein function.....	77
Companies developing cell-based protein assays.....	78
Determination of protein structure	79
X-Ray crystallography	79
Nuclear magnetic resonance.....	80
Electron spin resonance	80
Prediction of protein structure	80
Protein tomography.....	81
X-ray scattering-based method for determining the structure of proteins	82
Prediction of protein function	82

Three-dimensional proteomics for determination of function	82
An algorithm for genome-wide prediction of protein function	83
Protein function studies.....	83
Transcriptionally Active PCR	83
Protein-protein interactions	84
Bacterial protein interaction studies for assigning function	85
Bioluminescence Resonance Energy Transfer	85
Computational prediction of interactions	86
Detection Enhanced Ubiquitin Split Protein Sensor technology	86
Double Switch technology	86
Fluorescence Resonance Energy Transfer	86
In vivo study of protein-protein interactions	87
In vitro study of protein-protein interactions	87
Interactome	88
Membrane 1-hybrid method	88
Nanowire transistor for the detection of protein-protein interactions	89
Phage display	89
Protein affinity chromatography	89
Protein-fragment complementation system	89
Proximity-dependent hybridization chain reaction	90
Yeast 2-hybrid system	90
Companies with technologies for protein-protein interaction studies	91
Protein-DNA interaction	92
Monitoring protein function by expression profiling	93
Study of microprotein functions	93
Isotope-coded affinity tag peptide labeling	93
Differential Proteomic Panning	94
Cell map proteomics	94
Topological proteomics.....	95
Organelle or subcellular proteomics	96
SubCellBarCode	96
Nucleolar proteomics.....	97
Glycoproteomic technologies	97
High-sensitivity glycoprotein analysis	98
Fluorescent in vivo imaging of glycoproteins.....	98
Integrated approaches for protein characterization	98
Imaging mass spectrometry	99
IMS technologies	99
Applications of IMS	99
The protein microscope.....	100
Tag-Mass IMS.....	100
Quantitative immunofluorescence for proteomics	100
Automation and robotics in proteomics	101
Western blot	101
Limitations of WB.....	101
Innovations in WB.....	102
Capillary electrophoresis and WB	102
Chemiluminescent western blotting	102
Fluorescent WB.....	103
Microfluidics and WB	103
Multiplexing WB.....	104
Applications of Western blot	104
Research applications of Western blot.....	104
Molecular diagnostic applications of Western blot.....	104
Companies involved in Western blotting technologies	105
Laser capture microdissection	106
Microdissection techniques used for proteomics	106
Uses of LCM in combination with proteomic technologies	106
Concluding remarks about applications of proteomic technologies.....	107
NextGen Proteomics Platform	108
Precision proteomics	108

3. Protein biochip technology 109

Introduction 109

Types of protein biochips..... 110

ProteinChip	110
Applications and advantages of ProteinChip.....	111
ProteinChip Biomarker System	111
Matrix-free ProteinChip Array	112
Aptamer-based protein biochip	112
Fluorescence planar wave guide technology-based protein biochips.....	113

Lab-on-a-chip for protein analysis	113
Biochips for peptide arrays	114
Microfluidic biochips for proteomics	114
Protein biochips and microarrays for high-throughput expression	115
Nucleic Acid-Programmable Protein Array	115
High-density protein microarrays	115
HPLC-Chip for protein identification	116
Antibody microarrays	116
HuProt™ Human Proteome Microarrays	116
Integration of protein array and image analysis	117
Tissue microarray technology for proteomics	117
Protein biochips in molecular diagnostics	117
A force-based protein biochip	118
L1 chip and lipid immobilization	118
Multiplexed Protein Profiling on Microarrays	119
Live cell microarrays	119
ProteinArray Workstation	120
Proteome arrays	120
The Yeast ProtoArray	120
ProtoArray™ Human Protein Microarray	121
TRINECTIN proteome chip	121
Peptide arrays	122
Surface plasmon resonance technology	122
SPR Systems	122
FLEX CHIP	123
Combination of surface plasmon resonance and MALDI-TOF	123
Protein chips/microarrays using nanotechnology	124
Nanoparticle protein chip	124
Protein nanobiochip	124
Protein nanoarrays	125
Self-assembling protein nanoarrays	125
Companies involved in protein biochip/microarray technology	125
 4. Bioinformatics in Relation to Proteomics	 129
Introduction	129
Bioinformatic tools for proteomics	129
Testing of SELDI-TOF MS Proteomic Data	129
BioImagine's ProteinMine	130
Bioinformatics for pharmaceutical applications of proteomics	130
<i>In silico</i> search of drug targets by Biopendium	130
Compugen's LEADS	131
DrugScore	131
Proteochemometric modeling	131
Integration of genomic and proteomic data	132
Proteomic databases: creation and analysis	133
Introduction	133
Proteomic databases	133
GenProtEC	134
Human Protein Atlas	134
Human Proteomics Initiative	135
Human proteome map	136
International Protein Index	136
MS-based draft of the human proteome	136
Protein Structure Initiative – Structural Genomics Knowledgebase	136
Protein Warehouse Database	137
Protein Data Bank	137
Repository for raw data from proteomics MS	137
Universal Protein Resource	138
Protein interaction databases	138
Biomolecular Interaction Network Database	139
ENCODE	139
Functional Genomics Consortium	140
Human Proteinpedia	140
ProteinCenter	140
Databases of the National Center for Biotechnology Information	141
Application of bioinformatics for protein identification	141
Tandem MS for protein identification	141
Targeted MS for specific identification of proteins	141
Application of bioinformatics in functional proteomics	142
Use of bioinformatics in protein sequencing	142
Bottom-up protein sequencing	143

Top-down protein sequencing.....	144
Integration of next generation proteomics and gene sequencing data	144
Protein structural database approach to drug design	144
Bioinformatics for high-throughput proteomics.....	145
Bioinformatics for protein-protein interactions.....	146
Companies with bioinformatic tools for proteomics.....	146
 5. Research in Proteomics	 149
Introduction	149
Applications of proteomics in biological research	149
Identification of novel human genes by comparative proteomics	149
Study of relationship between genes and proteins.....	150
Characterization of histone codes.....	150
Structural genomics or structural proteomics.....	151
Protein Structure Factory	152
Protein Structure Initiative	152
Studies on protein structure at Argonne National Laboratory	153
Structural Genomics Consortium.....	153
Protein knockout	154
Antisense approach and proteomics	154
RNAi and protein knockout.....	154
Total knockout of cellular proteins.....	155
Ribozymes and proteomics	155
Single molecule proteomics	155
Single-molecule photon stamping spectroscopy	155
Single nucleotide polymorphism determination by TOF-MS.....	156
Application of proteomic technologies in systems biology	156
Signaling pathways and proteomics.....	157
Kinomics.....	157
Combinatorial RNAi for quantitative protein network analysis	157
Proteomics in neuroscience research.....	158
Stem cell proteomics	158
Comparative proteomic analysis of somatic cells, iPSCs and ESCs	159
hESC phosphoproteome.....	159
Proteomic studies of mesenchymal stem cells.....	159
Proteomics of neural stem cells.....	160
Proteome Biology of Stem Cells Initiative	160
Proteomic analysis of the cell cycle	161
Nitric oxide and proteomics	161
A proteomic method for identification of cysteine S-nitrosylation sites	161
Study of the nitroproteome	162
Study of the phosphoproteome.....	162
Study of the mitochondrial proteome	163
Proteomic technologies for study of mitochondrial proteomics	163
Cryptome	164
Study of protein transport in health and disease	164
Ancient proteomics.....	164
Proteomics research in the academic sector	165
Netherlands Proteins@Work	167
ProteomeBinders initiative.....	167
Rutgers University's Center for Integrative Proteomics Research.....	167
Vanderbilt University's Center for Proteomics and Drug Actions	168
 6. Pharmaceutical Applications of Proteomics	 169
Introduction	169
Current drug discovery process and its limitations	169
Role of omics in drug discovery	170
Genomics-based drug discovery.....	170
Metabolomics technologies for drug discovery	171
Role of metabolomics in drug discovery	171
Basis of proteomics approach to drug discovery.....	172
Proteins and drug action	172
Transcription-aided drug design.....	173
In vivo production of therapeutic proteins by mRNA	173
Role of proteomic technologies in drug discovery	173
Liquid chromatography-based drug discovery	174
Capture compound mass spectrometry	174
Protein-expression mapping by 2DGE	174
Protein-protein interactions and drug discovery	175
Role of MALDI mass spectrometry in drug discovery.....	175
Structural proteomics and drug discovery	176

Tissue imaging mass spectrometry	177
Oxford Genome Anatomy Project	178
Proteins as drug targets.....	178
Monitoring drug target binding using the cellular thermal shift assay	178
Ligands to capture the purine binding proteome	179
Chemical probes to interrogate key protein families for drug discovery	179
Global proteomics for pharmacodynamics	179
ProteoCarta® proteomics platform	180
ZeptoMARK™ protein profiling system	180
Role of proteomics in targeting disease pathways	181
Dynamic proteomics.....	181
Identification of protein kinases as drug targets.....	182
Mechanisms of action of kinase inhibitors.....	182
G-protein coupled receptors as drug targets.....	183
Methods of study of GPCRs	183
Cell-based assays for GPCR.....	183
Companies involved in GPCR-based drug discovery	184
GPCR localization database	185
Matrix metalloproteases as drug targets	185
Oligodendrocyte proteome as a target for antipsychotics	186
PDZ proteins as drug targets.....	186
Proteasome as drug target.....	186
Serine hydrolases as drug targets	187
Targeting mTOR signaling pathway	187
Targeting caspase-8 for anticancer therapeutics	188
Drug design based on structural proteomics.....	189
Protein crystallography for determining 3D structure of proteins	189
Automated 3D protein modeling	189
Drug targeting of flexible dynamic proteins	190
Companies involved in structure-based drug-design	190
Integration of genomics and proteomics for drug discovery	191
Ligand-receptor binding	192
Role of proteomics in study of ligand-receptor binding	192
Measuring drug binding of proteins	192
Aptamer protein binding	193
Systematic Evolution of Ligands by Exponential Enrichment	193
Aptamers and high-throughput screening.....	193
Nucleic Acid Biotools	194
Aptamer beacons.....	194
Peptide aptamers.....	195
Riboreporters for drug discovery	195
Target identification and validation	195
Application of mass spectrometry for target identification	196
Gene knockout and gene suppression for validating protein targets.....	196
Laser-mediated protein knockout for target validation	196
Integrated proteomics for drug discovery	197
High-throughput proteomics.....	197
Companies involved in high-throughput proteomics.....	198
Drug discovery through protein-protein interaction studies	198
Protein-protein interaction as basis for drug target identification	199
Protein-PCNA interaction as basis for drug design	199
Two-hybrid protein interaction technology for target identification	200
Biosensors for detection of small molecule-protein interactions.....	201
Protein-protein interaction maps	201
ProNet (Myriad Genetics)	201
Hybrigenics' maps of protein-protein interactions.....	201
CellZome's functional map of protein-protein interactions	202
Mapping of protein-protein interactions by mass spectrometry.....	203
Protein interaction map of Drosophila melanogaster	203
Protein-interaction map of Wellcome Trust Sanger Institute	203
Protein-protein interactions as targets for therapeutic intervention.....	203
Inhibition of protein-protein interactions by peptide aptamers	204
Selective disruption of proteins by small molecules	204
Post-genomic combinatorial biology approach	204
Differential proteomics	205
Shotgun proteomics.....	205
Hyper Reaction Monitoring	206
Targeted proteomics.....	206
Chemogenomics/chemoproteomics for drug discovery	207
Chemoproteomics-based drug discovery	208
Companies involved in chemogenomics/chemoproteomics	208

Activity-based proteomics	209
Locus Discovery technology.....	210
Automated ligand identification system.....	210
Expression proteomics: protein level quantification	211
Role of phage antibody libraries in target discovery	211
Analysis of posttranslational modification of proteins by MS	212
Phosphoproteomics for drug discovery	212
Application of glycoproteomics for drug discovery	213
Role of carbohydrates in proteomics.....	213
Challenges of glycoproteomics.....	213
Companies involved in glycoproteomics	214
Microproteins as targets for drug discovery.....	215
Role of protein microarrays/ biochips for drug discovery	215
Protein microarrays vs DNA microarrays for high-throughput screening	215
BIA-MS biochip for protein-protein interactions.....	216
ProteinChip with Surface Enhanced Neat Desorption.....	216
Protein-domains microarrays.....	216
Some limitations of protein biochips	217
Concluding remarks about role of proteomics in drug discovery.....	217
RNA versus protein profiling as guide to drug development	218
RNA as drug target	218
Combination of RNA and protein profiling.....	219
RNA binding proteins.....	219
Toxicoproteomics.....	219
Hepatotoxicity	219
Nephrotoxicity	220
Cardiotoxicity	221
Neurotoxicity	221
Protein/peptide therapeutics.....	221
Alphabody technology for improving protein therapeutics.....	221
Peptide-based drugs.....	222
Phylomer® peptides.....	222
Cryptein-based therapeutics.....	222
Synthetic proteins and peptides as pharmaceuticals	223
Genetic immunization and proteomics	224
Role of proteomics in synthetic antivenoms.....	224
Proteomics and gene therapy	225
Role of proteomics in clinical drug development.....	225
Pharmacoproteomics	225
Role of proteomics in clinical drug safety.....	226

7. Application of Proteomics in Human Healthcare	227
Introduction	227
Clinical proteomics	228
Definition and standards	228
Vermillion's Clinical Proteomics Program	228
Pathophysiology of human diseases	229
Diseases due to misfolding of proteins	229
Mechanism of protein folding.....	230
Nanoproteomics for study of misfolded proteins.....	231
Therapies for protein misfolding	231
Intermediate filament proteins	232
Significance of mitochondrial proteome in human disease	232
Proteome of <i>Saccharomyces cerevisiae</i> mitochondria.....	233
Rat mitochondrial proteome	233
Proteomic approaches to biomarker identification.....	234
The ideal biomarker	234
Proteomic technologies for biomarker discovery.....	234
MALDI mass spectrometry for biomarker discovery	235
Protein biochips/microarrays and biomarkers	235
Affinity proteomics for discovery of biomarkers.....	235
Antibody array-based biomarker discovery.....	236
Discovery of biomarkers by MAb microarray profiling.....	237
Tumor-specific serum peptidome patterns.....	237
Search for protein biomarkers in body fluids.....	237
Challenges and strategies for discovery of protein biomarkers in plasma.....	237
3-D structure of CD38 as a biomarker	239
BD™ Free Flow Electrophoresis System	239
Isotope tags for relative and absolute quantification.....	239
N-terminal peptide isolation from human plasma	240
Plasma protein microparticles as biomarkers	240

Proteome partitioning	240
SISCAPA method for quantitating proteins and peptides in plasma	241
Stable isotope tagging methods	241
Technology to measure both the identity and size of the biomarker	241
Biomarkers in the urinary proteome	242
Application of proteomics in molecular diagnosis	242
MassARRAY	243
Proximity ligation assay	244
Protein patterns	244
Proteomic tests on body fluids	244
Cyclical amplification of proteins	246
Applications of proteomics in infections	246
MALDI-TOF MS for microbial identification	246
Recognition of microbial glycans by human lectins	247
Role of proteomics in virology	247
Interaction of proteins with viruses	248
Quantitative temporal viromics	248
Role of proteomics in bacteriology	248
Epidemiology of bacterial infections	249
Proteomic approach to bacterial pathogenesis	249
Vaccines for bacterial infections	249
Protein profiles associated with bacterial drug resistance	250
Analyses of the parasite proteome	250
Application of proteomics in cystic fibrosis	251
Proteomics of cardiovascular diseases	251
Pathomechanism of cardiovascular diseases	251
Protein misfolding in cardiac dysfunction	252
Study of cardiac mitochondrial proteome in myocardial ischemia	252
Cardiac protein databases	252
Proteomics of dilated cardiomyopathy and heart failure	253
Proteomic biomarkers of cardiovascular diseases	253
Regulation of cardiac rhythmicity by Purkinje cell protein-4	254
Role of proteomics in cardioprotection	254
Role of proteomics in heart transplantation	254
Future of application of proteomics in cardiology	255
Proteomic technologies for research in pulmonary disorders	255
Application of proteomics in renal disorders	256
Diagnosis of renal disorders	257
Proteomic biomarkers of acute kidney injury	257
Cystatin C as biomarker of glomerular filtration rate	257
Protein biomarkers of nephritis	257
Proteomics and kidney stones	258
Proteomics of eye disorders	258
Proteomics of cataract	259
Proteomics of diabetic retinopathy	259
Retinal dystrophies	259
Use of proteomics in inner ear disorders	260
Use of proteomics in aging research	260
Alteration of glycoproteins during aging	261
Carbamylation of proteins with aging	261
Proteomics of muscle aging	261
Removal of altered cellular proteins in aging	262
Role of protein aggregation in aging and degenerative diseases	262
Study of the role of Parkin in modulating aging	263
Study of proteins that protect against hypoxic injury in age-related disorders	263
Proteomics and nutrition	263

8. Oncoproteomics

Introduction	265
Proteomic technologies for study of cancer	266
Application of CellCarta technology for oncology	266
Accentuation of differentially expressed proteins using phage technology	266
Cancer tissue proteomics	266
Dynamic cell proteomics in response to a drug	267
Desorption electrospray ionization for cancer diagnosis	267
Id proteins as targets for cancer therapy	268
Identification of oncogenic tyrosine kinases using phosphoproteomics	268
Laser capture microdissection technology and cancer proteomics	268
Mass spectrometry for identification of oncogenic chimeric proteins	269
Proteomic analysis of cancer cell mitochondria	269
Proteomic study of p53	270

Human Tumor Gene Index	270
Integration of cancer genomics and proteomics	270
Role of proteomics in study of cancer stem cell biology	271
Single-cell protein expression analysis by microfluidic techniques.....	271
Use of proteomics in cancers of various organ systems	271
Proteomics of brain tumors	271
Malignant glial tumors	271
Meningiomas	272
DESI-MS for intraoperative diagnosis of brain tumors	272
Proteomics of breast cancer	273
Integration of proteomic and genomic data for breast cancer	274
Proteomics of colorectal cancer	275
Proteomics of esophageal cancer	275
Proteomics of hepatic cancer	276
Proteomics of leukemia	276
Proteomics of lung cancer	277
Proteomics of pancreatic cancer	278
Proteomics of prostate cancer	278
Proteomics of renal cancer	279
Diagnostic use of cancer biomarkers	279
Proteomic technologies for tumor biomarkers	280
Nuclear matrix proteins (NMPs)	280
Antianneins as tumor markers in lung cancer	281
NCI's Network of Clinical Proteomic Technology Centers.....	281
Proteomics and tumor immunology	282
Proteomics and study of tumor invasiveness	282
Anticancer drug discovery and development	283
Anticancer drug targeting: functional proteomics screen of proteases	283
Kinase-targeted drug discovery in oncology	283
Protein-drug interactions in cancer	284
Role of proteomics in studying drug resistance in cancer	284
Small molecule inhibitors of cancer-related proteins	285
Future prospects of oncoproteomics	285
International oncoproteomic initiatives	285
Clinical Proteomic Tumor Analysis Consortium	286
Companies involved in application of proteomics to oncology	287

9. Neuroproteomics	289
Introduction	289
Application of proteomics for the study of nervous system	289
Proteomics of prion diseases	290
Normal function of prions in the brain	290
Detection of protein aggregates and prions	290
Diseases due to pathological prion protein	291
Transmissible spongiform encephalopathies	292
Creutzfeld-Jakob disease	292
Bovine spongiform encephalopathy	292
Variant Creutzfeldt-Jakob disease	292
Protein misfolding/aggregation in neurodegenerative disorders.....	293
Alzheimer disease	293
Amyotrophic lateral sclerosis	293
Common denominators of Alzheimer and prion diseases	294
Detection of misfolded proteins in neurodegenerative disorders	295
Ion channel link for protein-misfolding disease	295
Modulation of proteostasis in neurodegenerative disorders	296
Neurodegenerative disorders with protein abnormalities	296
Parkinson disease	298
Proteomics and glutamate repeat disorders	298
Proteomics and Huntington's disease	299
Targets to limit protein aggregation in neurodegenerative diseases	299
Aggregate contactome	299
Clusterin for clearance of aggregating misfolded proteins	300
Proteomics and demyelinating diseases	301
Proteomics of neurogenetic disorders	302
Fabry disease	302
GM1 gangliosidosis	302
Quantitative proteomics and familial hemiplegic migraine	303
Proteomics of spinal muscular atrophy	303
Proteomics of CNS trauma	303
Proteomics of traumatic brain injury	303
Chronic traumatic encephalopathy and ALS	305

Proteomics of cerebrovascular disease.....	305
Pathogenesis of cerebral small vessel disease.....	305
Proteomics of CNS aging.....	306
Protein aggregation as a biomarker of aging.....	306
Neuroproteomics of psychiatric disorders.....	306
Schizophrenia.....	307
Anxiety disorders.....	307
Depression and suicidal behavior.....	307
Neuroproteomic of cocaine addiction.....	308
Neurodiagnostics based on proteomics.....	308
Disease-specific proteins in the cerebrospinal fluid.....	308
Tau proteins.....	309
CNS tissue proteomics.....	310
Diagnosis of CNS disorders by examination of proteins in urine.....	311
Diagnosis of CNS disorders by examination of proteins in the blood.....	311
Serum pNF-H as biomarker of CNS damage.....	312
Intraoperative application of proteomics in surgery of brain tumors.....	312
Proteomics of BBB.....	313
Future of neuroproteomics in neurology.....	313
HUPO's Pilot Brain Proteome Project.....	314
 10. Proteomics Markets.....	 315
Introduction.....	315
Potential markets for proteomic technologies.....	315
Bioinformatics markets for proteomics.....	316
Markets for protein separation technologies.....	316
Markets for 2D gel electrophoresis.....	316
Market trends in protein separation technologies.....	316
Protein purification markets.....	317
Mass spectrometry markets.....	317
Markets for MALDI for drug discovery.....	317
Markets for nuclear magnetic resonance spectroscopy.....	318
Market for structure-based drug design.....	318
Markets for protein biomarkers.....	318
Markets for cell-based protein assays.....	318
Protein biochip markets.....	319
Western blot markets.....	319
Geographical distribution of proteomics technologies markets.....	319
Business and strategic considerations.....	320
Cost of protein structure determination.....	320
Opinion surveys of the scientist consumers of proteomic technologies.....	320
Opinions on mass spectrometry.....	320
Opinions on bioinformatics and proteomic databases.....	320
Systems for in vivo study of protein-protein interactions.....	320
Perceptions of the value of protein biochip/microfluidic systems.....	321
Small versus big companies.....	321
Expansion in proteomics according to area of application.....	321
Growth trends in cell-based protein assay market.....	321
Challenges for development of cell-based protein assays.....	322
Future trends and prospects of cell-based protein assays.....	322
Strategic collaborations.....	323
Analysis of proteomics collaborations according to types of companies.....	323
Types of proteomic collaborations.....	323
Proteomics collaborations according to application areas.....	324
Analysis of proteomics collaborations: types of technologies.....	324
Collaborations based on protein biochip technology.....	325
Concluding remarks about proteomic collaborations.....	325
Proteomic patents.....	326
Market drivers in proteomics.....	326
Needs of the pharmaceutical industry.....	326
Need for outsourcing proteomic technologies.....	327
Funding of proteomic companies and research.....	327
Technical advances in proteomics.....	327
Changing trends in healthcare in future.....	328
Challenges facing proteomics.....	328
Magnitude and complexity of the task.....	328
Technical challenges.....	328
Limitations of proteomics.....	329
Limitations of 2DGE.....	329
Limitations of mass spectrometry techniques.....	329
Complexity of the pharmaceutical proteomics.....	329

Unmet needs in proteomics	330
11. Future of Proteomics	331
Genomics to proteomics	331
Faster technologies	331
FLEXGene repository	331
Need for new proteomic technologies.....	332
Emerging proteomic technologies.....	333
Detection of alternative protein isoforms.....	333
Direct protein identification in large genomes by mass spectrometry	333
Proteome identification kits with stacked membranes	333
Vacuum deposition interface.....	334
<i>In vitro</i> protein biosynthesis	334
Proteome mining with adenosine triphosphate	334
Proteome-scale purification of human proteins from bacteria.....	334
Proteostasis network	335
Single cell proteomics.....	335
Fluorescent proteins for live-cell imaging	335
Live cell proteomics.....	335
Microfluidics for cell proteomics	336
Nanoscale study of cell proteomics.....	336
Membrane proteomics	337
Identification of membrane proteins by tandem MS of protein ions.....	337
Solid state NMR for study of nanocrystalline membrane proteins.....	338
Subcellular proteomics	338
Multiplex proteomics	338
High-throughput for proteomics.....	339
Future directions for protein biochip application	339
Bioinformatics for proteomics	339
High-Throughput Crystallography Consortium.....	340
Study of protein folding by IBM's Blue Gene	340
Study of proteins by atomic force microscopy	340
Population proteomics	341
Comparative proteome analysis.....	341
Human Proteome Organization	342
Cell-based Human Proteome Project.....	342
Human Salivary Proteome	343
Academic-commercial collaborations in proteomics	343
Indiana Centers for Applied Protein Sciences	343
Role of proteomics in the healthcare of the future.....	344
Proteomics and molecular medicine.....	344
Proteodiagnostics.....	344
Proteomics and personalized medicine.....	344
Targeting the ubiquitin pathway for personalized therapy of cancer	345
Protein patterns and personalized medicine.....	345
Personalizing interferon therapy of hepatitis C virus	347
Protein biochips and personalized medicine	347
Combination of diagnostics and therapeutics	347
Future prospects.....	347
12. References.....	349

Tables

Table 1-1: Landmarks in the evolution of proteomics	19
Table 1-2: Comparison of DNA and protein	29
Table 1-3: Comparison of mRNA and protein.....	29
Table 1-4: Methods of analysis at various levels of functional genomics.....	35
Table 2-1: Proteomics technologies.....	41
Table 2-2: Protein separation technologies of selected companies.....	46
Table 2-3: Companies supplying mass spectrometry instruments	55
Table 2-4: Companies involved in cell-based protein assays.....	78
Table 2-5: Methods used for the study of protein-protein interactions	84
Table 2-6: A selection of companies involved in protein-protein interaction studies	91
Table 2-7: Companies involved in Western blotting	105
Table 2-8: Proteomic technologies used with laser capture microdissection	107
Table 3-1: Applications of protein biochip technology	109
Table 3-2: Selected companies involved in protein biochip/microarray technology	125
Table 4-1: Proteomic databases and other Internet sources of proteomics information	133

Table 4-2: Protein interaction databases available on the Internet	139
Table 4-3: Bioinformatic tools for proteomics from academic sources	145
Table 4-4: Selected companies involved in bioinformatics for proteomics	146
Table 5-1: Applications of proteomics in basic biological research	149
Table 5-2: A sampling of proteomics research projects in academic institutions	165
Table 6-1: Pharmaceutical applications of proteomics	169
Table 6-2: Selected companies relevant to MALDI-MS for drug discovery	175
Table 6-3: Selected companies involved in GPCR-based drug discovery	184
Table 6-4: Companies involved in drug design based on structural proteomics	190
Table 6-5: Proteomic companies with high-throughput protein expression technologies	198
Table 6-6: Selected companies involved in chemogenomics/chemoproteomics	209
Table 6-7: Companies involved in glycoproteomic technologies	214
Table 7-1: Applications of proteomics in human healthcare	227
Table 7-2: Eye disorders and proteomic approaches	258
Table 8-1: Large scale international oncoproteomic initiatives	286
Table 8-2: Companies involved in applications of proteomics to oncology	287
Table 9-1: Neurodegenerative diseases with underlying protein abnormality	296
Table 9-2: Disease-specific proteins in the cerebrospinal fluid of patients	308
Table 10-1: Potential markets for proteomic technologies 2020-2030	315
Table 10-2: Geographical distribution of markets for proteomic technologies 2020-2030	319
Table 11-1: Role of proteomics in personalizing strategies for cancer therapy	345

Figures

Figure 1-1: A schematic miRNA pathway	22
Figure 1-2: Relationship of DNA, RNA and protein in the cell	30
Figure 1-3: Protein production pathway from gene expression to functional protein	33
Figure 1-4: Parallels between functional genomics and proteomics	33
Figure 2-1: Proteomics: flow from sample preparation to characterization	42
Figure 2-2: The central role of spectrometry in proteomics	49
Figure 2-3: Electrospray ionization (ESI)	50
Figure 2-4: Ion-mobility spectrometry-MS	52
Figure 2-5: Matrix-Assisted Laser Desorption/Ionization (MALDI)	53
Figure 2-6: Scheme of bio-bar-code assay	73
Figure 2-7: A diagrammatic presentation of yeast 2-hybrid system	91
Figure 2-8: A schematic view of SubCellBarCode	97
Figure 3-1: ProteinChip System	111
Figure 3-2: Surface plasma resonance (SPR)	123
Figure 4-1: Role of bioinformatics in integrating genomic/proteomic-based drug discovery	132
Figure 4-2: Bottom-up and top-down approaches for protein sequencing	143
Figure 6-1: Drug discovery process	170
Figure 6-2: Regulatory changes induced by drugs and implemented at the proteins level.	172
Figure 6-3: Relation of proteome to genome, diseases and drugs	173
Figure 6-4: The mTOR pathways	188
Figure 6-5: Steps in shotgun proteomics	206
Figure 6-6: Chemogenomic approach to drug discovery (3-Dimensional Pharmaceuticals)	208
Figure 8-1: Relation of oncoproteomics to other technologies	265
Figure 9-1: Identification of protein targets in neurodegenerative disorders	300
Figure 9-2: Clusterin bringing misfolded proteins into cells to be degraded by lysosomes	301
Figure 9-3: A scheme of proteomics applications in CNS drug discovery and development	314
Figure 10-1: Types of companies involved in proteomics collaborations	323
Figure 10-2: Types of collaborations: R & D, licensing or marketing	324
Figure 10-3: Proteomics collaborations according to application areas	324
Figure 10-4: Proteomics collaborations according to technologies	325
Figure 10-5: Unmet needs in proteomics	330
Figure 11-1: A scheme of the role of proteomics in personalized management of cancer	346